Yes, Bob, we know all of that. Thanks.
What do you think about the last financing? And, at $100/share, what do you think about the capitalization relative to competitors? BTW..... is Murex working on a follow-on project, and, now that they're no longer an independent biotech, what are our chances of following the work?
How are the margins on the sequencers going? Any improvement? Is the HLA system selling? What's the next source of cash going to be? What is the option ass'd with the Roche license?
This company made $20/share on the back of hard work by VGIN employees, a whim, and a prayer.
The price:book is 40. Do you care about stuff like that, or just about sticking the next guy? Either style of investing is fine by me. You play the game, you take your chances. However, this thread has been a repository of information relating to business success and scientific achievements. It serves a purpose, and I'd prefer that you start a new thread rather than attempt to change that purpose.
Thanks, Rick |
